Nanocor

NanoCor Therapeutics is a private biotechnology company focused on cardiovascular gene therapies, originally formed as a spinout of Asklepios BioPharmaceutical in 2005. The company has centered its development efforts on gene therapy for chronic heart failure, using adeno-associated virus delivery technologies and intracellular genetic protein therapy approaches. Its lead program, Carfostin (NAN-101), is designed to deliver a form of protein phosphatase inhibitor 1 to improve cardiac function in patients with heart failure. NanoCor has been described as operating from Chapel Hill, North Carolina, and remains a small private company with limited publicly disclosed corporate information. The company appears closely linked to AskBio for technology heritage and clinical development support.